Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

The efficacy of photopheresis for bronchiolitis obliterans syndrome after lung transplantation.

Morrell MR, Despotis GJ, Lublin DM, Patterson GA, Trulock EP, Hachem RR.

J Heart Lung Transplant. 2010 Apr;29(4):424-31. doi: 10.1016/j.healun.2009.08.029. Epub 2009 Oct 22.

PMID:
19853479
2.

A review of transfusion risks and optimal management of perioperative bleeding with cardiac surgery.

Despotis G, Eby C, Lublin DM.

Transfusion. 2008 Mar;48(1 Suppl):2S-30S. doi: 10.1111/j.1537-2995.2007.01573.x. Review. No abstract available.

PMID:
18302579
3.

Mortality and morbidity in pre-sensitized pediatric heart transplant recipients with a positive donor crossmatch utilizing peri-operative plasmapheresis and cytolytic therapy.

Holt DB, Lublin DM, Phelan DL, Boslaugh SE, Gandhi SK, Huddleston CB, Saffitz JE, Canter CE.

J Heart Lung Transplant. 2007 Sep;26(9):876-82.

PMID:
17845925
4.

Three new high-prevalence antigens in the Cromer blood group system.

Hue-Roye K, Lomas-Francis C, Belaygorod L, Lublin DM, Barnes J, Chung A, Fung-Kee-Fung K, Kinney J, Goldman-Lavi R, Yahalom V, Poole J, Ivankovic Z, Alcantara D, Bekavac M, Cepulic BG, Velliquette RW, Mason R, Reid ME.

Transfusion. 2007 Sep;47(9):1621-9.

PMID:
17725726
5.

Transfusion risks and transfusion-related pro-inflammatory responses.

Despotis GJ, Zhang L, Lublin DM.

Hematol Oncol Clin North Am. 2007 Feb;21(1):147-61. Review.

PMID:
17258124
6.

B-type natriuretic peptide measured during transfusion-related acute lung injury.

Edelson BT, Despotis GJ, Lublin DM.

Transfusion. 2006 Aug;46(8):1453-4. No abstract available.

PMID:
16934084
7.

Heparin low . . . photo no!

Edelson BT, Donnelly JK, Cox-Potter TS, Shah KS, Dynis MS, Lublin DM.

Transfusion. 2006 May;46(5):683-4. No abstract available.

PMID:
16686832
8.

The role of decay-accelerating factor as a receptor for Helicobacter pylori and a mediator of gastric inflammation.

O'Brien DP, Israel DA, Krishna U, Romero-Gallo J, Nedrud J, Medof ME, Lin F, Redline R, Lublin DM, Nowicki BJ, Franco AT, Ogden S, Williams AD, Polk DB, Peek RM Jr.

J Biol Chem. 2006 May 12;281(19):13317-23. Epub 2006 Mar 16.

9.

In-house validation of the BACTEC 9240 blood culture system for detection of bacterial contamination in platelet concentrates.

Dunne WM Jr, Case LK, Isgriggs L, Lublin DM.

Transfusion. 2005 Jul;45(7):1138-42.

PMID:
15987359
10.

Off-label use of recombinant factor VIIA concentrates after cardiac surgery.

Despotis G, Avidan M, Lublin DM.

Ann Thorac Surg. 2005 Jul;80(1):3-5. No abstract available.

PMID:
15975330
11.

Review: Cromer and DAF: role in health and disease.

Lublin DM.

Immunohematology. 2005;21(2):39-47. Review.

PMID:
15954803
12.
13.

Transfusion medicine service policies for recombinant factor VIIa administration.

Goodnough LT, Lublin DM, Zhang L, Despotis G, Eby C.

Transfusion. 2004 Sep;44(9):1325-31. Review.

PMID:
15318856
14.

Conformational defects slow Golgi exit, block oligomerization, and reduce raft affinity of caveolin-1 mutant proteins.

Ren X, Ostermeyer AG, Ramcharan LT, Zeng Y, Lublin DM, Brown DA.

Mol Biol Cell. 2004 Oct;15(10):4556-67. Epub 2004 Aug 10.

15.

SERF: a new antigen in the Cromer blood group system.

Banks J, Poole J, Ahrens N, Seltsam A, Salama A, Hue-Roye K, Storry JR, Palacajornsuk P, Ma BW, Lublin DM, Reid ME.

Transfus Med. 2004 Aug;14(4):313-8.

PMID:
15285728
16.

Non-ischemic left ventricular dysfunction after pediatric cardiac transplantation: treatment with plasmapheresis and OKT3.

McOmber D, Ibrahim J, Lublin DM, Saffitz JE, Ong-Simon C, Mendeloff EN, Huddleston CB, Canter CE.

J Heart Lung Transplant. 2004 May;23(5):552-7.

PMID:
15135370
17.

Role of the hydrophobic domain in targeting caveolin-1 to lipid droplets.

Ostermeyer AG, Ramcharan LT, Zeng Y, Lublin DM, Brown DA.

J Cell Biol. 2004 Jan 5;164(1):69-78.

18.

Autoantibody formation after alloimmunization: are blood transfusions a risk factor for autoimmune hemolytic anemia?

Young PP, Uzieblo A, Trulock E, Lublin DM, Goodnough LT.

Transfusion. 2004 Jan;44(1):67-72.

PMID:
14692969
19.

Antiadhesive role of apical decay-accelerating factor (CD55) in human neutrophil transmigration across mucosal epithelia.

Lawrence DW, Bruyninckx WJ, Louis NA, Lublin DM, Stahl GL, Parkos CA, Colgan SP.

J Exp Med. 2003 Oct 6;198(7):999-1010.

20.

Endocytosis of oxidized low density lipoprotein through scavenger receptor CD36 utilizes a lipid raft pathway that does not require caveolin-1.

Zeng Y, Tao N, Chung KN, Heuser JE, Lublin DM.

J Biol Chem. 2003 Nov 14;278(46):45931-6. Epub 2003 Aug 28.

21.

GUTI: a new antigen in the Cromer blood group system.

Storry JR, Sausais L, Hue-Roye K, Mudiwa F, Ferrer Z, Blajchman MA, Lublin DM, Ma BW, Miquel JF, Nervi F, Pereira J, Reid ME.

Transfusion. 2003 Mar;43(3):340-4.

PMID:
12675719
22.

Stabilization of caveolin-1 by cellular cholesterol and scavenger receptor class B type I.

Frank PG, Marcel YL, Connelly MA, Lublin DM, Franklin V, Williams DL, Lisanti MP.

Biochemistry. 2002 Oct 1;41(39):11931-40.

PMID:
12269838
23.
24.
25.

Accumulation of caveolin in the endoplasmic reticulum redirects the protein to lipid storage droplets.

Ostermeyer AG, Paci JM, Zeng Y, Lublin DM, Munro S, Brown DA.

J Cell Biol. 2001 Mar 5;152(5):1071-8.

27.

Universal RBCs.

Lublin DM.

Transfusion. 2000 Nov;40(11):1285-9. No abstract available.

PMID:
11099654
28.

Constitutive and growth factor-regulated phosphorylation of caveolin-1 occurs at the same site (Tyr-14) in vivo: identification of a c-Src/Cav-1/Grb7 signaling cassette.

Lee H, Volonte D, Galbiati F, Iyengar P, Lublin DM, Bregman DB, Wilson MT, Campos-Gonzalez R, Bouzahzah B, Pestell RG, Scherer PE, Lisanti MP.

Mol Endocrinol. 2000 Nov;14(11):1750-75.

PMID:
11075810
30.

Terminology for blood group antigens and genes-historical origins and guidelines in the new millennium.

Garratty G, Dzik W, Issitt PD, Lublin DM, Reid ME, Zelinski T.

Transfusion. 2000 Apr;40(4):477-89. No abstract available.

PMID:
10773062
31.

Role of decay-accelerating factor domains and anchorage in internalization of Dr-fimbriated Escherichia coli.

Selvarangan R, Goluszko P, Popov V, Singhal J, Pham T, Lublin DM, Nowicki S, Nowicki B.

Infect Immun. 2000 Mar;68(3):1391-9.

32.

Molecular basis of Cromer blood group antigens.

Lublin DM, Kompelli S, Storry JR, Reid ME.

Transfusion. 2000 Feb;40(2):208-13.

PMID:
10686005
34.

Expression and functional analysis of glycosyl-phosphatidyl inositol-linked CD46 in transgenic mice.

Shinkel TA, Cowan PJ, Barlow H, Aminian A, Romanella M, Lublin DM, Pearse MJ, d'Apice AJ.

Transplantation. 1998 Dec 15;66(11):1401-6.

PMID:
9869079
35.

Short consensus repeat domain 1 of decay-accelerating factor is required for enterovirus 70 binding.

Karnauchow TM, Dawe S, Lublin DM, Dimock K.

J Virol. 1998 Nov;72(11):9380-3.

36.

Survival of FimH-expressing enterobacteria in macrophages relies on glycolipid traffic.

Baorto DM, Gao Z, Malaviya R, Dustin ML, van der Merwe A, Lublin DM, Abraham SN.

Nature. 1997 Oct 9;389(6651):636-9.

PMID:
9335508
37.

Membrane cofactor protein (CD46) is a basolateral protein that is not endocytosed. Importance of the tetrapeptide FTSL at the carboxyl terminus.

Maisner A, Zimmer G, Liszewski MK, Lublin DM, Atkinson JP, Herrler G.

J Biol Chem. 1997 Aug 15;272(33):20793-9.

38.

Identification of a heparin binding domain in the seventh short consensus repeat of complement factor H.

Blackmore TK, Sadlon TA, Ward HM, Lublin DM, Gordon DL.

J Immunol. 1996 Dec 15;157(12):5422-7.

PMID:
8955190
39.

CD36 is palmitoylated on both N- and C-terminal cytoplasmic tails.

Tao N, Wagner SJ, Lublin DM.

J Biol Chem. 1996 Sep 13;271(37):22315-20.

40.

The HeLa cell receptor for enterovirus 70 is decay-accelerating factor (CD55).

Karnauchow TM, Tolson DL, Harrison BA, Altman E, Lublin DM, Dimock K.

J Virol. 1996 Aug;70(8):5143-52.

42.

Oligomerization of VIP21-caveolin in vitro is stabilized by long chain fatty acylation or cholesterol.

Monier S, Dietzen DJ, Hastings WR, Lublin DM, Kurzchalia TV.

FEBS Lett. 1996 Jun 17;388(2-3):143-9.

43.

Blood group antigens: so many jobs to do.

Lublin DM.

Transfusion. 1996 Apr;36(4):293-5. No abstract available.

PMID:
8623126
44.

Expression of functional decay-accelerating factor (CD55) in transgenic mice protects against human complement-mediated attack.

van Denderen BJ, Pearse MJ, Katerelos M, Nottle MB, Du ZT, Aminian A, Adam WR, Shenoy-Scaria A, Lublin DM, Shinkel TA, d'Apice AJ.

Transplantation. 1996 Feb 27;61(4):582-8.

PMID:
8610385
45.

Control of the complement system.

Liszewski MK, Farries TC, Lublin DM, Rooney IA, Atkinson JP.

Adv Immunol. 1996;61:201-83. Review.

PMID:
8834497
46.

Characterization of the echovirus 7 receptor: domains of CD55 critical for virus binding.

Clarkson NA, Kaufman R, Lublin DM, Ward T, Pipkin PA, Minor PD, Evans DJ, Almond JW.

J Virol. 1995 Sep;69(9):5497-501.

47.

Identification of complement regulatory domains in human factor H.

Gordon DL, Kaufman RM, Blackmore TK, Kwong J, Lublin DM.

J Immunol. 1995 Jul 1;155(1):348-56.

PMID:
7541419
49.

dra-related X adhesins of gestational pyelonephritis-associated Escherichia coli recognize SCR-3 and SCR-4 domains of recombinant decay-accelerating factor.

Pham T, Kaul A, Hart A, Goluszko P, Moulds J, Nowicki S, Lublin DM, Nowicki BJ.

Infect Immun. 1995 May;63(5):1663-8.

50.

Supplemental Content

Loading ...
Support Center